Sections
Wellbutrin is the weird cousin in the antidepressant family. Most of what people think of as antidepressants are SSRIs (selective serotonin reuptake inhibitors, the Zoloft/Lexapro/Prozac class), and they have a pretty consistent personality… they take the edge off, they flatten emotional range a bit, they kill libido for a chunk of patients, and a fair number of people gain weight on them. Wellbutrin doesn’t do any of that. It doesn’t touch serotonin at all. It works on dopamine and norepinephrine, which means it acts more like a mild stimulant than a sedating mood drug, which is the whole reason it gets a different slot in my head than the rest of the antidepressants.
Wellbutrin is the weird cousin in the antidepressant family.
That single fact reshapes the entire conversation about who it’s for. If you picture the SSRI patient as somebody who walks in wound tight, ruminating, can’t sleep, jumpy, jaw clenching, the Wellbutrin patient is the opposite kind of guy. Flat, slow, dragging, can’t get out of bed before 11, hasn’t been to the gym in months, doesn’t really enjoy what he used to enjoy. The classic low energy, anhedonic (the medical word for “stuff that used to be fun just doesn’t do it anymore”) depression. That patient on an SSRI often feels worse in the first month because you’ve taken somebody who’s already running at 40 percent and slowed them down further. Wellbutrin pushes the opposite direction, which for the right patient is exactly the thing.
The chemical name is bupropion. Been on the market since the late eighties, came back from a brief withdrawal in the nineties after some seizure issues at the original dosing got sorted out, and has been a workhorse antidepressant ever since.
Who it’s actually right for
The textbook Wellbutrin candidate is somebody with low energy depression who also has one or more of these going on… they’re a smoker, they’re worried about sexual side effects, they don’t want to gain weight, or they’ve already tried an SSRI and felt either nothing or worse.
The pattern looks like this. Picture a guy who comes in with classic anhedonic depression, sleeping eleven hours, dragging through the day, hasn’t gone to the gym in months, gained some weight, maybe just quit smoking three months earlier and is muscling through. His previous doctor put him on Lexapro and he lasted about five weeks before quitting because the bedroom stopped working and his weight was still climbing. He walks in pretty convinced antidepressants are a scam. Start Wellbutrin XL at 150 for two weeks, bump to 300, and at the six week follow-up he’s back at the gym, hasn’t relapsed on cigarettes, and his wife is happy again. That’s about as clean a Wellbutrin story as you’ll see in the room. Most aren’t that tidy, but the slot is real.
The sexual side effect piece is real and underdiscussed in clinical encounters where it should be discussed every time. SSRIs cause some degree of sexual dysfunction in something like 40 to 60 percent of patients (Montejo et al. 2001), and most patients won’t bring it up unless you ask directly. Guys under 50 in particular will quietly stop their medication rather than tell their psychiatrist their nethers aren’t working the way they used to. Wellbutrin doesn’t cause that, and it’s sometimes added to an SSRI specifically to rescue sexual function while keeping the SSRI’s serotonergic effect for mood or anxiety. That’s the augmentation move I reach for constantly, and it’s not getting talked about enough in primary care.
The weight thing matters too. SSRIs vary, but Paxil and Remeron in particular can put real weight on somebody over a year. Wellbutrin is weight neutral, sometimes mildly weight-losing in the first few months. For guys who already have a complicated relationship with the scale, that distinction can be the difference between staying on the medication and quitting. Not nothing.
SSRIs cause some degree of sexual dysfunction in something like 40 to 60 percent of patients, and most patients won’t bring it up unless you ask directly.
Who it’s wrong for, and this list matters
Three groups shouldn’t be on Wellbutrin, and one group should be on it cautiously.
Anyone with a history of an eating disorder, particularly bulimia or anorexia, is a hard no. The seizure risk goes up substantially in low-BMI patients and in patients who are purging, because electrolyte derangement plus a seizure-threshold-lowering drug is a recipe for a very bad day. This shows up on the FDA black box (the strongest warning label the FDA hands out, the rectangular boxed warning you see at the top of the package insert). I follow it strictly. If a patient tells me about a college bulimia history from many years back that’s fully resolved, I’ll consider it carefully, but active or recent eating disorder is a line I don’t cross.
Anyone with a seizure disorder or a history of seizures, same answer. Wellbutrin lowers the seizure threshold more than most psychiatric meds. The risk at therapeutic doses on the XL formulation is small, somewhere around 0.1 percent (Dunner et al. 1998), but it’s not zero, and there are plenty of other antidepressants that don’t have that issue.
Anyone with primary anxiety as the chief complaint. This is the one general practitioners get wrong the most. Somebody walks into their PCP describing panic attacks and gets handed Wellbutrin because it was the newest thing or because the doctor was worried about SSRI weight gain. Two weeks later the patient is more anxious, more wired, sleeping worse, and convinced all psychiatric medication is poison. Wellbutrin is an activator. It will reliably make a primary anxiety presentation worse. If anxiety is part of the picture but depression is the driver, sometimes you can still use it, sometimes paired with a short-term anxiolytic while it kicks in, but as a first-line for anxiety it’s the wrong tool.
The cautious group is anyone with a history of psychosis or mania. Dopaminergic drugs can destabilize bipolar patients into mania (the technical term for the elevated, agitated, sleepless-but-not-tired episode at the top of the bipolar swing). Not impossible to use, but you’d better know what you’re doing and stay in close contact with the patient.
The smoking cessation angle
Same molecule, different brand name, different FDA indication. Zyban is bupropion at the same dose range used for depression, marketed for smoking cessation. It works. The mechanism isn’t fully understood, but it dampens the dopamine reward associated with nicotine and seems to reduce the withdrawal misery in the first few weeks.
What I tell guys who smoke and are also depressed is that we get to address two things with one prescription, which is one of those rare two-birds wins. If you’re going to be on an antidepressant anyway, and you’ve been thinking about quitting cigarettes, Wellbutrin makes the cigarette quit about 60 percent more likely to stick six months out (Hajizadeh et al. 2023). Combine it with nicotine replacement and the numbers get better.
The other piece nobody mentions: a lot of depressed guys self-medicate with nicotine because it’s a mild dopamine and norepinephrine bump. Wellbutrin replaces some of that pharmacologically. Patients describe it as the first time in years they’ve gone a full day without thinking about a cigarette. Which is the kind of thing you don’t really appreciate until you’ve spent five years thinking about cigarettes constantly.
150 to 300mg XL
Almost everyone starts at 150mg XL for two weeks, then goes to 300mg XL. The 450mg dose exists and gets used occasionally, but seizure risk climbs above 450. The IR and SR formulations still exist but XL is cleaner.
Mornings only
Activating, so taking it at night will wreck your sleep. Patients on Wellbutrin who report insomnia have almost always been told to take it after dinner. Move it to 7 AM and the insomnia usually resolves in a week.
Four to six weeks
Energy can lift in the first week or two, which is misleading. Real mood improvement still takes the usual four to six weeks. The first two weeks people sometimes feel jittery. That mostly settles.
Things people don’t get told
It can make you sweaty. Not subtle. Some patients drip through dress shirts for the first month and then it settles, which is worth knowing before you take an important meeting in a gray shirt. It can also make you constipated and dry-mouthed. Both manageable. Both usually fade.
It isn’t a magic energy drug. The number of guys who heard from a friend that Wellbutrin gave him his life back and want to try it for fatigue or motivation without any actual depression… that’s a real conversation I have a lot. People sometimes conflate it with Adderall because they’ve heard the word “stimulant” attached to it somewhere. It’s a modest dopamine and norepinephrine reuptake inhibitor with mild activating properties, nothing close to a true stimulant. In a non-depressed person it’s mostly unremarkable, which honestly explains a lot about our industry’s expectation-setting around it.
It interacts with a real list of medications, especially other things that lower the seizure threshold. The Wellbutrin plus tramadol combination is one I always check for in patients coming over from another prescriber, because pain clinics and psychiatry don’t always talk to each other and tramadol is in a remarkable number of medicine cabinets.
The biggest thing patients aren’t told: if Wellbutrin worked and you stop, the relapse profile is similar to other antidepressants. People stop because they feel great, assume they’re cured, and rediscover the depression three months later. The right reason to taper off is a stable patient, a stable life, and a real plan with your prescriber. Not a Tuesday in March when you ran out of refills.
Where I land on the prescribing call
If a guy walks in and wants Wellbutrin and there’s no hard contraindication on the no-fly list above, he gets Wellbutrin. I’m a provider, not a parent. The honest take is mine to deliver, the call is his. If he’s pretty clearly an SSRI patient (heavy on the anxiety, mostly rumination, jaw clenching at 2 AM) and is dead set on Wellbutrin because he heard about it from a friend, the most I’ll do is make it a disapproving yes… he walks out with the script and a real conversation about what I’m worried about and what we’ll watch for. I hardly ever say no. The appointment isn’t mine, it’s his.
My personal view, which is one data point you can take or leave: most of what gets called depression in healthy guys with intact lives and decent sleep isn’t depression at all, it’s a life situation that’s been getting renamed for a long time. “Just stress” is what some guys have been calling depression for two years, “tough patch” is what others have been calling a marriage in trouble, “I just drink to unwind” is what gets called a drinking pattern that’s been getting away from somebody. The renaming doesn’t change what’s actually happening, and starting a medication on top of an unaddressed life situation tends to plateau at “less miserable but still stuck.” When the depression is real, though, Wellbutrin in the right slot is one of the cleanest, most useful tools we’ve got.
For the right person, Wellbutrin does work that almost nothing else does as cleanly… the sexual function piece, the weight piece, the smoking-cessation piece, the anhedonic-depression piece, all in one pill with a long, boring safety record. For the wrong person, it’s a fast way to make a bad situation worse. The trick is matching the tool to the case, which is most of what this job is anyway.
Sources
- Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs. Lancet. 2018;391(10128):1357-1366. PMID 29477251.
- Settle EC, Stahl SM, Batey SR, et al. Safety profile of sustained-release bupropion in depression: results of three clinical trials. Clin Ther. 1999;21(3):454-463. PMID 10321415.
- Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES). Lancet. 2016;387(10037):2507-2520. PMID 27116918.
- Hajizadeh A, Howes S, Theodoulou A, et al. Antidepressants for smoking cessation. Cochrane Database Syst Rev. 2023;5(5):CD000031. PMID 37230961.
- Montejo AL, Llorca G, Izquierdo JA, et al. Incidence of sexual dysfunction associated with antidepressant agents: a prospective multicenter study of 1022 outpatients. J Clin Psychiatry. 2001;62 Suppl 3:10-21. PMID 11229449.
- Dunner DL, Zisook S, Billow AA, et al. A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. J Clin Psychiatry. 1998;59(7):366-373. PMID 9714265.
